AR079657A1 - Formulacion de liberacion sostenida - Google Patents

Formulacion de liberacion sostenida

Info

Publication number
AR079657A1
AR079657A1 ARP100104811A ARP100104811A AR079657A1 AR 079657 A1 AR079657 A1 AR 079657A1 AR P100104811 A ARP100104811 A AR P100104811A AR P100104811 A ARP100104811 A AR P100104811A AR 079657 A1 AR079657 A1 AR 079657A1
Authority
AR
Argentina
Prior art keywords
release formulation
salt
sustained release
compound
average molecular
Prior art date
Application number
ARP100104811A
Other languages
English (en)
Inventor
Tomomichi Futo
Hikaru Taira
Seitaro Mizukami
Naoyuki Murata
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of AR079657A1 publication Critical patent/AR079657A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Una formulacion de liberacion sostenida que comprende un derivado de metastina y un copolímero de ácido láctico-ácido glicolico que tiene un peso molecular peso promedio de aproximadamente 5.000 a aproximadamente 40.000 o una sal del mismo. La formulacion de liberacion sostenida libera en forma lenta y estable el compuesto (1) o una sal del mismo durante mucho tiempo y ejerce un efecto medicinal del compuesto (1) o una sal del mismo durante un período de tiempo extenso. Además, la formulacion de liberacion sostenida que mejora la conveniencia del paciente reduciendo el numero de episodios de administracion. Reivindicacion 1: Una formulacion de liberacion sostenida caracterizado porque comprende un compuesto representado por la Formula: Ac-D--Tyr-Hyp-Asn-Thr-Phe--AzaGly-Leu-Arg (Me) -Trp-NH2 o una sal del mismo y un copolímero de ácido láctico-ácido glicolico que tiene un peso molecular peso promedio de aproximadamente 5.000 a aproximadamente 40.000 o una sal del mismo.
ARP100104811A 2009-12-22 2010-12-21 Formulacion de liberacion sostenida AR079657A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009290364 2009-12-22
JP2010144793 2010-06-25

Publications (1)

Publication Number Publication Date
AR079657A1 true AR079657A1 (es) 2012-02-08

Family

ID=43743497

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100104811A AR079657A1 (es) 2009-12-22 2010-12-21 Formulacion de liberacion sostenida

Country Status (26)

Country Link
US (2) US20120302508A1 (es)
EP (1) EP2515878B1 (es)
JP (3) JP2013514968A (es)
KR (1) KR20120098906A (es)
CN (2) CN102665690A (es)
AR (1) AR079657A1 (es)
AU (1) AU2010336168A1 (es)
BR (1) BR112012014947A2 (es)
CA (1) CA2785021C (es)
CO (1) CO6551752A2 (es)
CR (1) CR20120290A (es)
DO (1) DOP2012000171A (es)
EA (1) EA020865B1 (es)
EC (1) ECSP12011992A (es)
ES (1) ES2434315T3 (es)
IL (1) IL219967A0 (es)
MA (1) MA33910B1 (es)
MX (1) MX2012006441A (es)
NZ (1) NZ600157A (es)
PE (1) PE20121481A1 (es)
SG (1) SG181436A1 (es)
TN (1) TN2012000255A1 (es)
TW (1) TW201125575A (es)
UY (1) UY33127A (es)
WO (1) WO2011078394A2 (es)
ZA (1) ZA201203775B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2585091B1 (en) * 2010-06-25 2014-09-10 Takeda Pharmaceutical Company Limited Sustained-release formulation comprising a metastin derivative
WO2016020901A1 (en) 2014-08-07 2016-02-11 Acerta Pharma B.V. Methods of treating cancers, immune and autoimmune diseases, and inflammatory diseases based on btk occupancy and btk resynthesis rate
IL311335A (en) 2016-09-30 2024-05-01 Sumitomo Pharma Switzerland Gmbh Methods for treating female infertility

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9211268D0 (en) * 1992-05-28 1992-07-15 Ici Plc Salts of basic peptides with carboxyterminated polyesters
FR2693905B1 (fr) * 1992-07-27 1994-09-02 Rhone Merieux Procédé de préparation de microsphères pour la libération prolongée de l'hormone LHRH et ses analogues, microsphères et formulations obtenues.
WO2001078687A1 (en) * 2000-04-18 2001-10-25 Peptron Inc. Injectable sustained release pharmaceutical composition and processes for preparing the same
AR023940A1 (es) * 2000-05-03 2002-09-04 Eriochem Sa Procedimiento para la produccion de microcapsulas de liberacion prolongada de peptidos solubles en agua
EP1317304B1 (en) * 2000-09-01 2011-04-27 Palmaya Pty Ltd. Slow release pharmaceutical preparation and method of administering same
WO2002043709A1 (fr) * 2000-12-01 2002-06-06 Takeda Chemical Industries, Ltd. Procede de production d'une preparation contenant une substance bioactive
JP2003002841A (ja) * 2001-04-20 2003-01-08 Takeda Chem Ind Ltd ペプチド含有製剤
WO2002085399A1 (en) * 2001-04-20 2002-10-31 Takeda Chemical Industries, Ltd. Peptide-containing preparations
KR20050090420A (ko) * 2002-12-26 2005-09-13 다케다 야쿠힌 고교 가부시키가이샤 메타스틴 유도체 및 이의 용도
SG153865A1 (en) 2004-06-25 2009-07-29 Takeda Pharmaceutical Metastin derivatives and use thereof
TW200613012A (en) * 2004-07-02 2006-05-01 Takeda Pharmaceuticals Co Sustained-release composition, process for producing the same and use of the same
CN1923284A (zh) * 2005-08-30 2007-03-07 孔庆忠 抗癌药物缓释注射剂及其应用
UA97236C2 (en) * 2005-12-22 2012-01-25 Такеда Фармасьютикал Компани Лимитед Metastin derivatives and use thereof
US8404643B2 (en) * 2005-12-22 2013-03-26 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
TWI386417B (zh) * 2005-12-22 2013-02-21 Takeda Pharmaceutical 轉移抑素衍生物及其用途
KR101522035B1 (ko) * 2006-12-18 2015-05-20 다케다 야쿠힌 고교 가부시키가이샤 서방성 조성물 및 이의 제조 방법
JPWO2009131191A1 (ja) * 2008-04-24 2011-08-25 武田薬品工業株式会社 メタスチン誘導体およびその用途
PE20110939A1 (es) * 2008-12-29 2012-01-19 Takeda Pharmaceutical Agente preventivo/terapeutico contra el cancer
RU2582678C2 (ru) * 2010-08-13 2016-04-27 Эйлерон Терапьютикс, Инк. Пептидомиметические макроциклы

Also Published As

Publication number Publication date
NZ600157A (en) 2013-07-26
WO2011078394A3 (en) 2012-03-15
BR112012014947A2 (pt) 2019-09-24
ECSP12011992A (es) 2012-07-31
ZA201203775B (en) 2013-08-28
MA33910B1 (fr) 2013-01-02
JP6472730B2 (ja) 2019-02-20
AU2010336168A1 (en) 2012-06-14
IL219967A0 (en) 2012-07-31
SG181436A1 (en) 2012-07-30
DOP2012000171A (es) 2012-08-31
UY33127A (es) 2011-07-29
JP2013514968A (ja) 2013-05-02
US20120302508A1 (en) 2012-11-29
PE20121481A1 (es) 2012-11-12
EP2515878A2 (en) 2012-10-31
WO2011078394A2 (en) 2011-06-30
CR20120290A (es) 2012-09-06
CA2785021C (en) 2019-03-05
JP2016029045A (ja) 2016-03-03
EP2515878B1 (en) 2013-10-30
CN107412725A (zh) 2017-12-01
CO6551752A2 (es) 2012-10-31
ES2434315T3 (es) 2013-12-16
CN102665690A (zh) 2012-09-12
TW201125575A (en) 2011-08-01
KR20120098906A (ko) 2012-09-05
JP2017160201A (ja) 2017-09-14
CA2785021A1 (en) 2011-06-30
US20180228732A1 (en) 2018-08-16
TN2012000255A1 (en) 2013-12-12
EA020865B1 (ru) 2015-02-27
EA201290372A1 (ru) 2012-12-28
MX2012006441A (es) 2012-06-28

Similar Documents

Publication Publication Date Title
CY1120564T1 (el) Υδατικα εναιωρηματα tmc278
CY1118232T1 (el) Διαμορφωτες φαρμακοκινητικων ιδιοτητων θεραπευτικων παραγοντων
AR107864A1 (es) ÁCIDO 7a,11b-DIHIDROXI-6a-ETIL-5b-COLAN-24-OICO Y COMPOSICIONES FARMACÉUTICAS
DOP2012000011A (es) Formulacion farmaceutica
CY1119730T1 (el) Παραγωγα καρβοξυλικου οξεος πυρρολιδινης ως αγωνιστες του συζευγμενου με πρωτεϊνή-g υποδοχεα 43 (gpr43), φαρμακευτικη συνθεση και μεθοδοι για χρηση στην αντιμετωπιση μεταβολικων διαταραχων
CY1116688T1 (el) Τροποποιητες φαρμακοκινητικων ιδιοτητων θεραπευτικων ειδων
CU23814A3 (es) Emulsión intravenosa de butilftalida y aplicación de la misma
AR072261A1 (es) Derivados piperazin-pirazolicos, composiciones farmaceuticas que los contienen y usos de los mismos como agentes anticancerigenos.
BRPI1002601E2 (pt) composição nanoestruturada de uso veterinário para administração de fármacos
GT201400069A (es) Composiciones farmaceuticas
EA200901423A1 (ru) Бензимидазолы и содержащие их фармацевтические композиции
SV2011003907A (es) Composiciones antimicrobianas
ECSP13012812A (es) Formulaciones inmunosupresoras
AR077225A1 (es) Formulaciones inyectables que contienen asenapina y metodo de tratamiento que las utiliza
BR112015011430A2 (pt) composição para liberação imediata e prolongada
CY1115556T1 (el) Φαρμακευτικη συνθεση για χορηγηση απο το στομα η οποια περιλαμβανει ετεξιλικη δαβιγατρανη
UY35211A (es) Compuestos tricíclicos
CY1116012T1 (el) Ενωσεις πυραζολιου ως ανταγωνιστες toy crth2
AR079657A1 (es) Formulacion de liberacion sostenida
GT201500038A (es) Composicion de difenidol de liberacion prolongada.
DOP2012000304A (es) Formulacion de liberacion sostenida
ECSP12012352A (es) Agente terapéutico de liberación sostenida para la hipertensión y la disfunción renal
UY37798A (es) Composiciones sólidas orales de betahistina de liberación prolongada no pulsátil
TH118942A (th) สูตรผสมที่ปลดปล่อยเป็นเวลานาน
BR112015005489A2 (pt) composição farmacêutica para administração oral com dissolução e/ou absorção aperfeiçoadas

Legal Events

Date Code Title Description
FA Abandonment or withdrawal